1Trivers KF, I.und M J, Porter PI., et al. The epidemiology of triple-negative breasl cancer[J], including race, 2009, 20(7):1071.
2Rakha EA, El-Sayed ME, Green AR, et al. Prognostic markers in triple negative breast cancer [J ]. Cancer, 2007,109(1) :25.
3Dolle JM,Daling JR,White E, et al. Risk factors for triple- negative breast cancer in women under the age of 45 years[J]. Cancer Epidemiol Biomarkers Prev, 2009, 18 (4):1157.
4Young SR, Pilarski RT, Donenberg T, et al. The prevalence of BRCAl mutations among young women with triple-negative breast cancer[J]. BMC Cancer, 2009,9 ( 1 ) 86.
5Alli E, Sharma VB, Sunderesakumar P, et al. Defective repair of oxidative DNA damage in triple-negative breast cancer confers sensitivity to inhibition of Poly(ADP-Ribose) polymerase[J]. Cancer Res, 2009,69 (8) : 3589.
6Toyama T, Yamashita H, Kondo N,et al. Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers [J].BMC Cancer, 2008,8(3) :309.
7Lin NU,Claus E,Sohl J,et al. Sites of distant recurrence and clinical outcomes in patients with metastatic triple- negative breast cancer: high incidence of central nervous system metastases[J]. Cancer, 2008,113 (10) : 2638.
9Uematsu T, Kasami M, Yuen S. Triple negative breast cancer: correlation between MR imaging and pathologic findings[J ]. Radiology, 2009,250 ( 3 ) : 638.
10Freedman GM, Anderson PR, Li T, et al. Locoregional recurrence of triple -negative breast cancer after breast -conserving surgery and radiation[J]. Cancer, 2009,115 (5) 946.
2Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Aead Sei U S A, 2001,98:10869-10874.
3Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tmnours. Nature. 2000. 406,747-752.
4Potemski P, Kusinska R, Watala C, et al. Prognostic relevance of basal cytokeratin expression in operable breast cancer. Oncology, 2005, 69:478-485.
5Abd El-Rehim DM, Pinder SE, Paish CE, et al. Expression d luminal and basal cytokeratins in human breast carcinoma. J Pathol, 2004, 203:661-671.
6van de Rijn M, Perou CM, Tibshirani R, et al. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol, 2002, 161:1991-1996.
7Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A, 2003, 100:8418-8423.
8Livasy CA, Karaca G, Nanda R, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol, 2006, 19:264-271.
9Rakha EA, Putti TC, Abd El-Rehim DM, et al. Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation. J Pathol, 2006, 208:495-506.
10Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res, 2004, 10:5367-5374.
2Trivers KF,Lund MJ,Porter PL,et al.The epidemiology of triple-negative breast cancer,including race.Cancer Causes Control,2009,20(7):1071～1082.
3Dolle JM,Daling JR,White E,et al.Risk factors for triple-negative breast cancer in women under the age of 45 years.Cancer Epidemiol Biomarkers Prev,2009,18(4):1157～1166.
4Liedtke C,Mazouni C,Hess KR,et al.Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.J Clin Oncol,2008,26(8):1275～1281.
5Wang S,Yang H,Tong F,et al.Response to neoadjuvant therapy and disease free survival in patients with triple-negative breast cancer.Gan To Kagaku Ryoho,2009,36(2):255～258.
6Uhm JE,Park YH,Yi SY,et al.Treatment outcomes and clinicopathologic characteristics of triple-negative breast cancer patients who received platinum-containing chemotherapy.Int J Cancer,2009,124(6):1457～1462.
7Perou CM,Sorlie T,Eisen MB,et al.Molecular portraits of human breast tumours. Nature . 2000
8Cleator S,Heller W,Coombes R C,et al.Triple-negative breast cancer: therapeutic options. Lancet Oncology,The . 2007
9Zhou P,RechtA.Young age and outcome forwomen with early-stage invasive breast carcinoma[].Cancer.2004
10Aebi S,Gelber S,Castiglione-Gertsch M,et al.Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer[].The Lancet.2000
